• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Solid Biosciences Management to Host Call on April 27, 2022 to Discuss Updated Corporate Strategy and First Quarter 2022 Financial Results

    4/25/22 8:00:00 AM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SLDB alert in real time by email

    CAMBRIDGE, Mass., April 25, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that it will release first quarter 2022 financial results before the market opens on Wednesday, April 27, 2022. Management will host a conference call on the same date beginning at 8:00 a.m. ET to discuss the Company's financial results and a strategic update to develop SGT-001 and SGT-003 pipeline programs for Duchenne.

    A live webcast of the call will be available on the Company's website at www.solidbio.com under the "News & Events" tab in the Investor Relations section, or by clicking here. Participants may also access the call by dialing +1 866-763-0341 (domestic) or +1 703-871-3818 (international), referencing Conference ID# 6545417.

    The archived webcast will be available in the "News and Events" section of the Company's website.

    About Solid Biosciences

    Solid Biosciences is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with Duchenne. Disease-focused and founded by a family directly impacted by Duchenne, our mandate is simple yet comprehensive – work to address the disease at its core by correcting the underlying mutation that causes Duchenne with our lead gene therapy candidate, SGT-001, as well as our recently announced next-generation gene therapy candidate, SGT-003. For more information, please visit www.solidbio.com.

    Investor Contacts:

    David Carey

    FINN Partners

    212-867-1768

    [email protected]

    Caitlin Lowie

    Solid Biosciences

    607-423-3219

    [email protected]

    Media Contact:

    Erich Sandoval

    FINN Partners

    917-497-2867

    [email protected]



    Primary Logo

    Get the next $SLDB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SLDB

    DatePrice TargetRatingAnalyst
    1/8/2025$16.00Buy
    Truist
    12/13/2024$16.00Outperform
    Wedbush
    12/10/2024$15.00Mkt Outperform
    JMP Securities
    7/15/2024$10.00 → $15.00Neutral → Overweight
    JP Morgan
    6/24/2024$12.00Market Perform → Outperform
    Leerink Partners
    5/31/2024$20.00Overweight
    Piper Sandler
    3/28/2024$40.00Outperform
    William Blair
    3/15/2024$16.00Buy
    Citigroup
    More analyst ratings

    $SLDB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Truist initiated coverage on Solid Biosciences with a new price target

      Truist initiated coverage of Solid Biosciences with a rating of Buy and set a new price target of $16.00

      1/8/25 8:30:04 AM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Wedbush initiated coverage on Solid Biosciences with a new price target

      Wedbush initiated coverage of Solid Biosciences with a rating of Outperform and set a new price target of $16.00

      12/13/24 8:18:51 AM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • JMP Securities initiated coverage on Solid Biosciences with a new price target

      JMP Securities initiated coverage of Solid Biosciences with a rating of Mkt Outperform and set a new price target of $15.00

      12/10/24 8:02:56 AM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care